{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"5.0","upperLimit":"10.8","value":"7.6"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"357"}],"units":"Participants"}],"description":"Residual cancer was defined as tumor found by pathology in a therapeutic shave after the SOC surgical procedure was completed; that is, tumor that current Standard of Care (SOC) surgery failed to remove. LUM Imaging System was used during the surgery, but the assessment of the outcomes was unknown until the pathology report was available.","dispersionType":"95% Confidence Interval","groups":[{"description":"The LUM Imaging Device was used to examine inside the lumpectomy cavity to determine if the dye indicated any areas that might contain residual tumor. If the imaging tested positive for the cancer cells remaining in the lumpectomy cavity, the surgeon would remove an additional piece of tissue. This process was continued until a negative reading from the device was obtained or a maximum of 2 shaves of additional tissue had been removed. Patients in this arm received the study drug, LUM015.\n\nStudy Device Arm: LUM015 was administered 2 to 6 hours prior to surgery. The LUM Imaging device was used to assist in the removal of additional tumor tissue.","id":"OG000","title":"Device Intervention: LUM Imaging System Used"}],"paramType":"NUMBER","populationDescription":"modified intent to treat population (mITT) includes subjects injected with LUM015 and LUM Imaging was performed","reportingStatus":"POSTED","timeFrame":"Day 1, during surgery","title":"Percentage of Patients Who Had Residual Cancer Found in at Least One LUM Imaging System Guided Shave Among All Patients.","type":"PRIMARY","unitOfMeasure":"percentage of participants"}